Cargando…

Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)

Background: Targeting the CD47/SIRPα signaling pathway represents a novel approach to enhance anti-tumor immunity. However, the crystal structure of the CD47/SIRPα has not been fully studied. This study aims to analyze the structure interface of the complex of CD47 and IMM01, a novel recombinant SIR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Jifeng, Li, Song, Chen, Dianze, Liu, Dandan, Guo, Huiqin, Yang, Chunmei, Zhang, Wei, Zhang, Li, Zhao, Gui, Tu, Xiaoping, Peng, Liang, Liu, Sijin, Bai, Xing, Song, Yongping, Jiang, Zhongxing, Zhang, Ruliang, Tian, Wenzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457805/ https://www.ncbi.nlm.nih.gov/pubmed/36080360 http://dx.doi.org/10.3390/molecules27175574

Ejemplares similares

IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells
por: Yu, Jifeng, et al.
Publicado: (2022)

SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal
por: Yu, Jifeng, et al.
Publicado: (2022)

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy
por: Li, Song, et al.
Publicado: (2023)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling
por: Li, Song, et al.
Publicado: (2023)

Membrane-Mediated Cooperative Interactions of CD47 and SIRPα
por: Li, Long, et al.
Publicado: (2023)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021)

CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)

SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis
por: Li, Yiqing, et al.
Publicado: (2023)

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
por: Zhang, Wenting, et al.
Publicado: (2020)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

CD47/SIRPα axis: bridging innate and adaptive immunity
por: van Duijn, Anneloes, et al.
Publicado: (2022)

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
por: Li, Chang, et al.
Publicado: (2022)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
por: Zhang, Jin, et al.
Publicado: (2018)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019)

Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma
por: Hutter, Gregor, et al.
Publicado: (2019)

Binding Mechanism of CD47 with SIRPα Variants and Its Antibody: Elucidated by Molecular Dynamics Simulations
por: Huang, Kaisheng, et al.
Publicado: (2023)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
por: Liao, Haiqin, et al.
Publicado: (2022)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
por: Luo, Xukai, et al.
Publicado: (2023)

The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era
por: Montero, Enrique, et al.
Publicado: (2023)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
por: Qu, Tailong, et al.
Publicado: (2022)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

Augmentation of CD47/SIRPα signaling protects cones in genetic models of retinal degeneration
por: Wang, Sean K., et al.
Publicado: (2021)

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
por: Xiao, Amy, et al.
Publicado: (2022)

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
por: Chang, Rui, et al.
Publicado: (2023)

Novel CD47: SIRPα Dependent Mechanism for the Activation of STAT3 in Antigen-Presenting Cell
por: Toledano, Natan, et al.
Publicado: (2013)

Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors
por: Miller, Thomas W., et al.
Publicado: (2019)

Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy
por: Huang, Bo, et al.
Publicado: (2021)

Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetite
por: Gupta, Ajay, et al.
Publicado: (2020)

SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation
por: Dehmani, Safa, et al.
Publicado: (2021)

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
por: Behrens, Leonie M., et al.
Publicado: (2022)

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies
por: Andrechak, Jason C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hv14jk6bij4jmjrafmsaia6sfe